<SEC-DOCUMENT>0001193125-13-310599.txt : 20130730
<SEC-HEADER>0001193125-13-310599.hdr.sgml : 20130730
<ACCEPTANCE-DATETIME>20130730172959
ACCESSION NUMBER:		0001193125-13-310599
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20130726
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Shareholder Nominations Pursuant to Exchange Act Rule 14a-11
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20130730
DATE AS OF CHANGE:		20130730

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ARCA biopharma, Inc.
		CENTRAL INDEX KEY:			0000907654
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				363855489
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-22873
		FILM NUMBER:		13996892

	BUSINESS ADDRESS:	
		STREET 1:		8001 ARISTA PLACE
		STREET 2:		SUITE 430
		CITY:			BROOMFIELD
		STATE:			CO
		ZIP:			80021
		BUSINESS PHONE:		720-940-2200

	MAIL ADDRESS:	
		STREET 1:		8001 ARISTA PLACE
		STREET 2:		SUITE 430
		CITY:			BROOMFIELD
		STATE:			CO
		ZIP:			80021

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NUVELO INC
		DATE OF NAME CHANGE:	20030203

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HYSEQ INC
		DATE OF NAME CHANGE:	19970610
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d576784d8k.htm
<DESCRIPTION>8-K
<TEXT>
<HTML><HEAD>
<TITLE>8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>WASHINGTON, D.C. 20549 </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>FORM 8-K
</B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>CURRENT REPORT </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>Pursuant to Section&nbsp;13 or 15(d) </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>of the Securities Exchange Act of
1934 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Date of Report (Date of earliest event reported): July&nbsp;30, 2013 (July 26, 2013) </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>ARCA biopharma, Inc. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(Exact Name of Registrant as Specified in Charter) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Delaware</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>000-22873</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>36-3855489</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(State or Other Jurisdiction</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>of Incorporation)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Commission</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>File Number)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(I.R.S. Employer</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Identification No.)</B></FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>8001 Arista Place, Suite 430, Broomfield, CO 80021 </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Address of Principal Executive Offices) (Zip Code) </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(720) 940-2200 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Registrant&#146;s telephone number, including area code)
</B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Not Applicable </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>(Former Name or Former Address, if Changed Since Last Report) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:10px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain
Officers; Compensatory Arrangements of Certain Officers. </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On July&nbsp;26, 2013, the Board of Directors (the
&#147;Board&#148;) of ARCA biopharma, Inc. (the &#147;Company&#148;) elected Raymond L. Woosley, M.D., Ph.D. as a director of the Company to fill a newly created seat on the Board. Dr.&nbsp;Woosley was elected for a term expiring at the
Company&#146;s 2015 annual stockholders&#146; meeting. Dr.&nbsp;Woosley was also appointed to serve on the Board&#146;s Compensation and Nominating and Corporate Governance Committees. A copy of the press release relating to Dr.&nbsp;Woosley&#146;s
appointment is attached hereto as Exhibit 99.1. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dr.&nbsp;Woosley is currently the President, Emeritus, of the Critical Path
Institute (C-Path), a non-profit, public-private partnership with the United States Food and Drug Administration, of which he was a founder, and where he served as President, Chief Executive Officer and Chairman of the Board from 2005 to
2011.&nbsp;Since 2012, Dr.&nbsp;Woosley is also the President and Chairman of the Board of the Arizona Center for Education and Research on Therapeutics (AzCERT), an independent, nonprofit research and education organization dedicated to the safe
use of medicines. Since 2001, Dr.&nbsp;Woosley has also been a Professor of Medicine and Pharmacology at The University of Arizona Health Sciences Center, and Professor, Emeritus, since 2012, where he was also Vice President for Health Sciences from
2001 to 2005, and Dean of the College of Medicine from 2001 to 2002.&nbsp;From 1988 to 2000, Dr.&nbsp;Woosley was a professor of pharmacology and medicine at the Georgetown University School of Medicine, where he was also Director of the Institute
of Cardiovascular Sciences from 1994 to 2000, and Division Chief, Clinical Pharmacology, in the Department of Medicine from 1988 to 1994.&nbsp;Dr.&nbsp;Woosley earned his Ph.D. in Pharmacology from the University of Louisville, and his M.D. from the
University of Miami.</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In connection with his appointment, and pursuant to the Company&#146;s previously adopted director
compensation policy, the Company granted Dr.&nbsp;Woosley an option to purchase 1,250 shares of common stock at an exercise price of $1.40 per share, the closing price of the Company&#146;s common stock on July&nbsp;26, 2013. The option is subject
to the terms and conditions of the Company&#146;s 2004 Equity Incentive Plan, as amended (the &#147;Plan&#148;), and the Company&#146;s standard forms of Option Grant Notice and Option Agreement for the Plan, copies of which are filed as Exhibits
10.38 and 10.36 respectively to the Company&#146;s Annual Report on Form 10-K filed on March&nbsp;26, 2009. The option vests in three annual installments on the annual anniversary the date of grant, assuming Dr.&nbsp;Woosley&#146;s continued service
on the Board for such periods. On the same date, the Company also resumed paying compensation to its existing non-employee directors by granting to Dr.&nbsp;Linda Grais and Dr.&nbsp;John Zabriskie options to purchase 583 shares of common stock at an
exercise price of $1.40 per share, the closing price of the Company&#146;s common stock on July&nbsp;26, 2013. The options are subject to the terms and conditions of the Plan and the Company&#146;s standard forms of Option Grant Notice and Option
Agreement for the Plan. The options vest in equal monthly installments and will be fully vested as of December&nbsp;31, 2013, assuming Drs. Grace and Zabriskie&#146;s continued service on the Board for such periods. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In connection with Dr.&nbsp;Woosley&#146;s election, Dr.&nbsp;Woosley and the Company also entered into an Indemnity Agreement in the
same form as has previously been entered into with the Company&#146;s other directors.&nbsp;The Indemnity Agreement generally requires the Company to indemnify Dr.&nbsp;Woosley against liabilities incurred in the performance of his duties to the
Company to the maximum extent permitted by Delaware corporate law and the Company&#146;s certificate of incorporation and bylaws.&nbsp;The Company&#146;s standard form of Indemnity Agreement is filed as Exhibit&nbsp;10.52 to its Annual Report on
Form 10-K filed on March&nbsp;26, 2009. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Also on July&nbsp;26, 2013, Jean-Francois Formela, M.D. notified the Board of his
resignation as a Director of the Board. Dr.&nbsp;Formela&#146;s resignation not to stand for re-election is not the result of any disagreements with the Company relating to its operations, policies or practices. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;5.08. Shareholder Director Nominations. </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">On July&nbsp;26, 2013, the Board approved September&nbsp;17, 2013 as the date of the Company&#146;s Annual Meeting. The Board also approved July&nbsp;30, 2013 as the record date for stockholders entitled
to notice of and to vote at the Annual Meeting. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Because the Annual Meeting will be held more than 30 days from the calendar
date of the Company&#146;s 2012 Annual Meeting of Stockholders, the due dates for the provision of any qualified stockholder proposal or qualified stockholder nominations under the rules of the SEC and the bylaws of the Company listed in the
Company&#146;s 2012 Proxy Statement on Schedule 14A as filed with the SEC on April&nbsp;5, 2012 are no longer applicable. Such nominations or proposals, including any notice on Schedule 14N, are now due to the Company no later than August&nbsp;9,
2013. The Company currently intends to make its proxy materials available beginning on or about August&nbsp;8, 2013. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Section&nbsp;9 &#151;
Financial Statements and Exhibits </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;9.01. Financial Statements and Exhibits. </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) Exhibits. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:28pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit<BR>Number</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:39pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release titled &#147;Raymond L. Woosley, M.D., Ph.D. Appointed to ARCA biopharma Board of Directors&#148; dated July&nbsp;30, 2013.</FONT></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SIGNATURES </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dated: July&nbsp;30, 2013 </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARCA biopharma, Inc.</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(Registrant)</FONT></P></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Patrick M. Wheeler</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Patrick M. Wheeler</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chief Financial Officer</FONT></TD></TR>
</TABLE></DIV>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>INDEX TO EXHIBITS </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:28pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit<BR>Number</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:39pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release titled &#147;Raymond L. Woosley, M.D., Ph.D. Appointed to ARCA biopharma Board of Directors&#148; dated July&nbsp;30, 2013.</FONT></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d576784dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 99.1 </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right">


<IMG SRC="g576784g40h95.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>RAYMOND L. WOOSLEY, M.D., PH.D. APPOINTED TO ARCA BIOPHARMA BOARD OF DIRECTORS </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Broomfield, CO, July&nbsp;30, 2013</I> &#150; ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted
therapies for cardiovascular diseases, today announced that Raymond L. Woosley, M.D., Ph.D, has been appointed to the Company&#146;s Board of Directors. He will serve on the Compensation and Nominating and Corporate Governance Committees of the
Board of Directors. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dr.&nbsp;Woosley is currently the President, Emeritus, of the Critical Path Institute (C-Path), a non-profit,
public-private partnership with the United States Food and Drug Administration, of which he was a founder, and where he served as President, Chief Executive Officer and Chairman of the Board from 2005 to 2011.&nbsp;Since 2012, Dr.&nbsp;Woosley is
also the President and Chairman of the Board of the Arizona Center for Education and Research on Therapeutics (AzCERT), an independent, nonprofit research and education organization dedicated to the safe use of medicines. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;We are honored to have Dr.&nbsp;Woosley join the ARCA Board of Directors,&#148; said Dr.&nbsp;Michael&nbsp;R. Bristow, President and Chief
Executive Officer of ARCA. &#147;With his extensive expertise and decades-long experience in cardiovascular clinical pharmacology, anti-arrhythmic therapeutics, pharmacogenetic drug development and regulatory science, Dr.&nbsp;Woosley will be a
valuable addition to the ARCA Board as we continue the development of Gencaro.&#148; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;I am delighted to join the Board of an
organization focused on advancing cardiovascular science and potentially improved medical therapeutics,&#148; said Dr.&nbsp;Woosley. &#147;ARCA&#146;s personalized medicine approach and its comparative effectiveness clinical trial of Gencaro
incorporate important aspects of what I believe will be more efficient, informative and effective drug development in the future.&#148; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Since
2001, Dr.&nbsp;Woosley has also been a Professor of Medicine and Pharmacology at The University of Arizona Health Sciences Center, and Professor, Emeritus, since 2012, where he was also Vice President for Health Sciences from 2001 to 2005, and Dean
of the College of Medicine from 2001 to 2002.&nbsp;From 1988 to 2000, Dr.&nbsp;Woosley was a professor of pharmacology and medicine at the Georgetown University School of Medicine, where he was also Director of the Institute of Cardiovascular
Sciences from 1994 to 2000, and Division Chief, Clinical Pharmacology, in the Department of Medicine from 1988 to 1994.&nbsp;Dr.&nbsp;Woosley earned his Ph.D. in Pharmacology from the University of Louisville, and his M.D. from the University of
Miami.</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dr.&nbsp;Woosley is a former member of the National Academy of Science&#146;s Institute of Medicine&#146;s Drug Forum, and his research
has been published in over 265 peer-reviewed publications and 50 book chapters. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">ARCA also announced that Jean-Francois Formela, M.D., Partner at Atlas Ventures, resigned from the ARCA
Board of Directors. Dr.&nbsp;Formela has been a member of ARCA&#146;s Board of Directors since February 2006. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;We thank Jean-Francois
for his leadership and service over the past seven years as a Director for ARCA,&#148; said Dr.&nbsp;Bristow. &#147;His experience and insight into the pharmaceutical industry have served the company well and directly contributed to the Company
reaching its current state, approaching the launch of GENETIC-AF, our Phase 2B/3 clinic trial of Gencaro.&#148; </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>About ARCA biopharma
</B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">ARCA biopharma is dedicated to developing genetically-targeted therapies for cardiovascular diseases. The
Company&#146;s lead product candidate, Gencaro</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">TM</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2">
(bucindolol hydrochloride), is an investigational, pharmacologically unique beta-blocker and mild vasodilator being developed for atrial fibrillation. ARCA has identified common genetic variations that it believes predict individual patient response
to Gencaro, giving it the potential to be the first genetically-targeted atrial fibrillation prevention treatment. ARCA has a collaboration with Medtronic, Inc. for support of the Phase 2B portion of the GENETIC-AF trial. For more information please
visit <U>www.arcabiopharma.com</U>. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Safe Harbor Statement </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">This press release contains &#147;forward-looking statements&#148; for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. These statements include, but are not
limited to, statements regarding the potential impact of ARCA&#146;s personalized medicine approach to drug development and the comparative effectiveness GENETIC-AF trial, the potential for genetic variations to predict individual patient response
to Gencaro, Gencaro&#146;s potential to treat atrial fibrillation, future treatment options for patients with atrial fibrillation, and the potential for Gencaro to be the first genetically-targeted atrial fibrillation prevention treatment. Such
statements are based on management&#146;s current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including,
without limitation, the risks and uncertainties associated with: the Company&#146;s financial resources and whether they will be sufficient to meet the Company&#146;s business objectives and operational requirements; results of earlier clinical
trials may not be confirmed in future trials, the protection and market exclusivity provided by the Company&#146;s intellectual property; risks related to the drug discovery and the regulatory approval process; and, the impact of competitive
products and technological changes. These and other factors are identified and described in more detail in ARCA&#146;s filings with the SEC, including without limitation the Company&#146;s annual report on Form 10-K for the year ended
December&nbsp;31, 2012, and subsequent filings. The Company disclaims any intent or obligation to update these forward-looking statements. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Contact: </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Derek Cole </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Investor Relations Advisory Solutions </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">720.940.2163, <U>derek.cole@arcabiopharma.com</U> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2">### </FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g576784g40h95.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g576784g40h95.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`3P#:`P$1``(1`0,1`?_$`+P````&`P$!````````
M```````&!P@)"@$$!0,"`0$```<!`0$``````````````0($!@<("0,%"A``
M``8!`P($`P0(!0$)`````0(#!`4&!P`1""$2,2(3"4$4%5%Q,E)AD;'10J(C
M"H&A)"46,_""0S0U)A<8>!$``0,#`@,#!@D)"`,``````0`"`Q$$!2$&,1('
M05$387&!(C((D:'10E(S%"0)\+'!X6)RDM(CLD-SHT2T%24F-CC_V@`,`P$`
M`A$#$0`_`+[5DL<14X=]/S\@SBH>,;G=/Y!\L"#9JBGMN<YQW$1,/E*4`$QC
M"``&^OB[@W%A-K8J7-9^XCML=`TN<]YH*#N[SW!5%M9W=_*VUL&>)=O-&M[U
M'9=/<4C$))5ACNBFG&R2ARIRUBDQBTWI2&,456L8S1<O"HJ;;E.H8@]H]2@/
M37-?J'^)'@L3E7V/3K$MR=G&XM=-</?$PN&GJ\@<2*]JS'A.CMW=6XFS$SX'
MTKRL:'4\Y)182]P#)2Q4U"XKJWIJ!T-]<F/Q%Z'`/]'L(%$=63#^(YU(GB,D
M6U,22?9^]7.O^6OHLZ08ITWA.OIP._D9\JZ1^>&2TT$5S8OJW]<%Q2*$S->8
M45/3'S?)[;`/CJI/XB'5%MFV\?M+$B)S7?ZJY]II`(^K\Z]6=(<"ZY=;G(7%
M&MK]6SY5QU_<(R(U`AG&+JL3N,8!*$W,B82$$`.8@_)]H^/3<>NJ-GXC_4;0
M3;5Q#26-</O5SJ"*G^[[%[P]&<).UIBR%P7.KIR,[/2E[P_SAI&0Y1I6[1%G
MHL\^4308+.GJ3R"?N5#>F1J#T"HK1SE978"$7)L;?8##K8OHM[^'3SJ3?1;?
MW(S_`(S<DL@8&M+G0\VOSW@&FG&BLG=/2S,8$/N+2L]DP5)H`X#S`D'T)ZY'
M1C!U*4!Z=.X=^H;[B&W3<0Z>/3KK>WF%'2:&W(!8X:\P(X_'HL65/,X`>JWB
MOOUQ_*'ZQU/4'4<%&H.HX(>N/Y0_6.B(M6^\U3'U>E;=>K+7JA580B*LM8['
M+M(:%C$G3E!FV-(2+]1!JT]9VY32)W&\ZBA2EZCHB[[=Z#A(BZ?I*)*D(JBJ
MDH51)5)4@*$42.41!1(Q3!L</*8.H;AHB]O7'\H?K'1%RY>QP\`U!].RD7#,
MQ4*B1Y+2+*,:'<*=WI-@=/UVZ/KJ[#VEW$1`!Z:(M5O<:P\1%9G8ZZZ3[0."
MC>>BW"0E'80-WIN1)VB`^.^VB+FN<DT-D<$WMVIC-0>@$=VN!;'$=]O*120[
MAV'Q^.B(QQTU'3#4KV(?,)5H;\+N,>MWS,P;;[D<MCJ(G$/B!3"(:(MWUQ_*
M'ZQT1#UQ_*'ZQT18,Y["&4.4"D)N)SB;M(F4`$3'4,(=I"%`-Q$>@!XZ(F[7
M3F+Q2QV^-%7KDG@FI2I-^^.G<ITUB^3[3]AP49K2Z;A,Y3`("`@`E'QT1>E9
MY@<5KJHFE3^26!K(LM_TF\3EFD.UU?T)I)3(J&']&V^B)<(FQQ,^W!W!R<3,
ML]Q`7D1)LY1J!R]AA3^88JK)>IZ:I1VW#H/V"`Z(NMZX_E#]8Z(@+@0Z]F_Z
M`'J._3X]`T1%A2^U!.XDQX:SUPM\4KIK>C2QFF/_`"I:JIO/IBEA2@A5"0-#
MDD_].+D">B"OE$V^B(S`N80`>T/#X#O_`)AN`Z(OH%Q$0#M#Q^W1%L:(HT/<
M0M\HT9X^I#1<R,;,FF)Z42!02%D#PYV*$:T4`I@[R)N70J;&`2]P`/B`:Y@?
MB/;[S6,QN%Z?V#VQX[*Q3S3'4./@/C8&@@<")#74+,W27$P7+KG*.($\#V-;
M7N<'$_F"851*0,\Z20W31<+&#Y,5S"=NH8P[BV.N/9\N=0_0##TW'QZZYL;$
MZ?OW7DVXYS?"M2VD,;>7^H\"NI:::@$^L5FG*YBXQL3I.?Q+<M]<_0'?30\:
M#0%.SIF(OJ#.8AU8XQ)N,2&3;,UDSD54,T,!)6-*42]XF%N<%T]OQ"3IN`ZW
M7Z?]$+*YQEQ8W$)&:MHB\1D4<6CM%=#Z"2>Y8PO]US1D749^[.=0'R^;C\2.
MSO#BSZ&H;=BT*+F7^L($`X&[0-]6+VF5``ZIIH")CCX%(`AK(LO0^TN]I;?@
MM[9YGO;B9T@Y""&DN<"ZH%!3O7R6;N`OY7R24`;3MXTX<.SXTC]RQ21](R",
M2V].,B"G0,[5W(T0:,B>FH\?.#%$I!=JE$Y"@'J',<"AX:P%O_HQ!+D[AV):
M1CK-OA>*UI+>9NCFU`["".[RJZL3GKJ../FT<345(K3BFBV:!"+>*&0%0R1#
MCVG5*9(5034`X'(4!$Q-^T#!^W6F.X<3<X'+$6-+>]C>',>!1SRT\VA`TJ`>
M-%E*RG&1MC]OE'@D:@U-0?0>U3E\9K9(7;!^/YZ6.9>1^E'BG;@PB)W!X5PM
M%%<J&,(F,HJDV*(B.XB(]=?H5]U_>^1WWT+P6XLC62\="8GDZDF%SHSQ[BVA
M\RT_WO91XG<%S86PJU[ZCS.U2]>'36P`(<.8<"K78WD8&=P`^!#13*LI_<2\
MB)@U!I_$VE)/Y`C]NWS+G52.24<(0%$82Z=:H$?/.6X`1@QL-Q?BKLIMW&;(
M^.^B*3SVCN3`\G^#N*;#+/\`YR]8Y:GQ'D#UE2&=FG*2@W9QTDY+T/\`[U6E
M&3H#F_&8YNHB`Z(I+]$26Y?PGB;/M14H.:<?5?)E+4?-)0:U;8I&6C`E60G*
MSDD4E1(=N]:%6/V*D.4Q`,.WCHBI&>];Q0Q-PYY*4^!P'&25)I61,7?\W7IJ
M-@G'T5!3;2Q2D,Y+`B^>KN&\.\0:I&%NHJ8$E`$2;$$"@16&>%_M.<"7_%W!
MMHO>`ZWDVYWG%-)N%IMM[>S\S+R,Q:J\PF7XH$&5191R"*KP2)$;II]A2AU$
M>NB*,OW4N([WVS7>-.5O!/(61\$5R?N!J9;:+"76>?U2$GEFCF9@9**B)E[)
M-'D%,-HYPT>1CY-TV`P$,GZ>XZ(ISO;`YIO><W%J$RC9F,=&9)K$[(X^R:SB
M2&1BW%HA&[)T2>C&QC'%HPL46_0=`CN((*F43`1*4!T1.&Y5\GL7\0L*6G-N
M6)%=M`0*:32+B(\I%)RVV5^*B<-5:^@H($5DI1=,0$YA!)L@4ZZHE23,8"*M
MW@A]S5]\/)5GL.1\C6G`/!ZCS(1\K2,6RSB$"S/"C\PVI*$ND=-S;+$,>X(>
M5DWIE6+`%>U!OZ@E`"*P!A_V\.$V"H%O`X_XSXE*4J":;F:M%0B;M:I%8"`5
M5S*V:X-9J6>.5C")C#ZI4^X1`"`'@1(?RG]H?A+R>KDDU6P]4<3WY5HN$%DW
M%,!&5";BI,R)@:N).)AVS*OV.-*L("X;.VYO4*&Q%$S;&T1-&]D'%UZXN63F
M_P`.,FG:GMN(\JTBWL7;0RQ6%EJ5VJ;IE#VZ%1<"99.(G$:\DL!#;F16$Z1A
M[B:(I^=$6J^<MF+)V]?ND6#%HU<.WCYR<B;9HS;)&6=.EU%1!,B#=`AC',8>
MTI0$1Z!HBH\#[BEF:^[Q5>9DP66C,1VBRML:5@D@W619R/%]_*O\>(S;`RH@
MF^8GD6*\Z90FY/FT3?Q%$0(KQJ1TU$TE$3D5252(JDHD/>FHB<I3$4(8NX"F
M8IP$!\-AT1>H>(?>'[=$6_HBBW]P)'UKKB8#`4Y`A;+NFH4#I&_W&'ZG*/4?
M#[0UR'_$I]??>S87$F-UA?59\UW]:VXGL6?^CK0<1DG?.$L7]EZ(V+(2JNTD
M4)1-W$*""91>L2)NV:8J['_KL5%$W(!MYOZ:A@*7?H&K1Z-;=V4^T@,[)K+(
MDCEDA!=RN.@.A[]/2H[@N<D)G,B'-'K5I[0$ZJQW)"B&J<2S4B+-<G#-5S%6
M(GS`IM:TH)V*"DFGWI?/.%#@)$B*".Q2CN([==SMV;N'3:/%8&.*VR>\IX*L
MG;R\S(^44\44!X4K6JL.QQ\^9DN+F;FBQK:T'8'>3]7:E.J1[,^C2/G,BQ6!
M%`_8V,R8HIID7)_63:"@BD=H"O=U$@AN.LD;(R&Z\KAG9;)S1/9$TGD+0&T=
M[;(_5I76@I1?*OX[:W:UK-90!4ZZD=Z)-Z@X!Y7VNTDSKE<1.(KP[5FJ]E'T
MVW$044<%]5(C@6X@7TC*&$A=]Q`=6UOC;V)N=MMO<7(,=@7AY=`QO-)(\FKG
M24U!!J&U/`JJQ]]>&=I-7.[^P#N'Z>_M*CJRK&0Y#.B1;(Z9`[Q*O(.2+R"A
M!`W>/HM?3;-@[_PAYQV\=<M.MF*P,#99L3$[F8#5[A0^<+-NW;RYD$;)#4'B
MI).')!)Q\IA1#;9>Q;?=]>?ZZD^XW_\`-6"_Q;O_`'$RP9U'_P#<Y/W1^8)T
M&MM6>P/,%9IXKD6">BJK!3%GGWJ$;`5V*D9R<DG1RI-V$3$M%7[]XLJ80(FD
MW:H'.81'X:F4%`OQ%P*'N"X-YZ\G,HL#INN?+ZS8_P`0A)^J"E6PEC#YR%Q)
M\L90!%F@M:6!)%0"B'J*MP/XB&B*-#V!\[S&#.6&4^).053Q(Y7:239K&/1%
M,&69,3K2#5^U!)82&[Y6#;O42@.QE#-$@Z]-$5R\?$?'_'Q_QWZZ(L:(J:G]
MRB&_)_!'_P">I0>FV_2]RX[=1`.NVB*TYPX*/_U(XP@4IC;<?\1&[NH%W-1(
M,=@V*/<(;]=$4&W]PSG*NV2@X7X>4A4EXS3<,I1MV>T:J;S]DBXB$BY&,@B.
MH:.(Y>ED+)-312-6W8"QR('4$`3#N$BD`]GCAU=N''$M"N921^0RADVV/,EW
M"O`JFL-/^H1<9&0E4=*HG4;JRT9$QY#O!(82D<+&3#?T^XQ%`U_<6<@9VW\F
MJ1QY8O%B5##%%8VM[&`8192.0L@(K.DW;E(#"5=:/JZ+9%(1#=,'*VWXM$5H
M?@C@F"XV\2,$8I@V9&R\/0("8LZWI$(K*76S1[>?MDF],4I3.':TQ(*E`YMS
M`D0A?`H`!$[;1$-$1>:U.L,K+)W)I7H1K;9N-CX:8LS:*8(3TK#Q*CI:)BI*
M83;ED7T?&*O53-T55#$2,H82@&XZ(C#HBBM]V[-%GIO'&*P!BUTH3.G,B[17
M'/&K1FH8)%E'6]1!O?+*B4H"8&L'5UE045`.U,7)1$?*.B*);WT>"=6Q3Q5X
MJ7[&D(F2%X[PD'QVM*K-'M6<4N3:`O69MT5(`[2I71JY%90?$\N;KYM$4P?M
M#\ES\G.#N*IR7D/J-YQHV5P[?SJ*D,[/,T9!LTB95P(&%17ZY5U&+@3F#^JJ
M<XB(B4=$4G(>(?>'[=$6_HBC`Y\N56UXQ0=,`'_8[)U,5%0`'ZG#?^$L0X&$
M0UR2_$=NIK?J!LT1L:]AQ]]7F`(^NMN((*SYT?;$[#Y(/<6GQ8J4)^B_N6OA
M^;L!FS55):OQC`#"4LC-QD`U:IB7<`(@55B,@_6/MW`5$IQ'X:J.B&8R[+*"
M:!N)M;9E"Z22&)S6:<7-\,\WP'BJ;=%J6%\K99R34`-<^IKIV'3TZ+>Y!-9E
MM-UW+,+W62OMHE"L6F1CHUR@VAI".<.'#>0%B"0"6-=)OS)BIT*FLGN;;?7U
MO>'QN;QV;Q?6?:+O^6PKK1MKD'6L?A^'(`VLD,8:PEH+#S%H%0=>*HMFR1R6
M\^W+AS8WT+VF0@DT\]=>_P`B]ZQG-F=DT8,WY7"KP4D$6K</4<*"H!2$(@@0
M3+&4'?RAL.XZKMF==K6YQT>!Q=S+/"P58P1O\0/=VN#FBC17A6@[E'([:BMH
MOM,[F.:17X=4OR,C)0U1292,O"UZQRQW$THQL4=ZR)FKORMD?F7*2C9JX!%,
MOJ`;<I#&Z[=0UL3;SY+%;'CCR-[:LSESSR!MS;L<)034<KBQU`RO*:TU(5EC
M[)+>AK?%\-NE6$BAKK4`BOG3$,TS,VF"R4B1B3U`_HJMHF(^65`4Q,`M73-J
M#9P4P=2B4_4.NN<?O`9C.'Q+')V^/$<C2.>&.,:<:U:P$<%F3:\-HV2(QNG+
MQPYG.(X'B"4_7AVJ*O'^G''J/S%BW'M*0/\`UY_X%+Y2_P"&ND?N1`#W;L%3
M0>+=_P"YF6&^HX_\SD_='Y@G/`&_A_VV#?6U[/8'F"LT\5#9[S>7+8GA+'_#
M[$+K?-?-N^1V(8%LFLHBK'T@SQH:[3+P[<IW+6-43<-V:RH%'_3+KB7J00U,
MH(Y8IQ=[IF&,;4/$U%;^W9'U#'-6AJ?76VW(,5RQD&R;LTG3E1-LD11^^.D*
MRX@0H*+',8=M]]$59'W#\=\D^$?/2G<DL@M,6161;U:(OD+".\)&M*>/7$[6
MY=FRM,:U"WHI32$A*F0!1\B?<A@D!.0=C&T17CL4Y*KF8L98_P`K5)R1U6\B
MU"O7"'5(;U.UG/QJ+\C=0P=`<-#J&25#Q*HF(#UT1*#HBIJ_W)YA)RAP.8!V
M$O'N3$!V`W7_`)W+_P`(@(#]VPZ(G]2WMDW>_<",87;C#R6Y3T?,#W!-!NK&
MDO,^760QE;W[JE0\D\I"$&M(H!5$)'N.A''9G(@T/Z9#)BD([$4>OL6\H<<8
MBY)VW!N?*97&&3,KSJ[.FYCN<2@XR;"9'CSK1TGC.S6N7*O,-$+"J@8K4HJ$
M[))$Z1A."R?817.0VW$=A`=^NY1`1$!$.NX!OL.B*B+[]53E*A[BUWL;Q%<8
MZZXZQC<X0YTC)D=(1D1_QUVFBJ/E.1*3KRI#!N'CX:(KN&%[C%Y"P]BN]P;A
M)U#7#'=+L<8N@J5=,[67KD:](!52B('%,5A*(_:`Z(E+T1#1%@!WWVW'8=C=
M!\OC^+IY?#XZ(L_$`W`!,.P`(@&XB.P`&XAU$=$5;R3DN1O.#W1\@YDXP%PG
M+TCV_8Y;"U(<9T7NHT!_DRV-7Y;[8H5*C-E7KVS1JZ3EN183^DDV;('#S&`P
M$3M>2&"_=&Y*8.R5@^_H^WXO6,A5MQ%/1@5L]I3C5R@HE(Q<A"+RC-5BWF64
MHP04;*+!Z::B>YNG31%"K[`&?I#"/+7)/%.[N%(MGF!A),6L8\5!$(_,>*5'
MZ;EF=%0"^B\E(!%^W,4``5%6B90#H``17.2CN)1#P'80^X?`?N'1%OZ(HLO<
M22=MK#BF4(10K<L9:&97(%W2!V#F)<E0.;P`QTB"(?=KDQ^)/97S\_M?(Q-I
M90V-Z'R'0-)EMR&U[S0T'D6?.C4D'V&_@>&NE=+%0$ZTY7IKN.K>@"Q3S#E1
M)LD)/54(('=..P0$K5N4QNT@GV\1V[`ZAU`-:A](][PV\K8<E,Z/'APJUQJ7
M`=CF'U>4\.)X\%?^?Q\?AD6K!ST]8GYGE`[=>^B?-2<LIK`ZDW22*%?KD69M
M!UUN;N:.'LF;Y5BU<^H?9\X,(G774.`B)2"/3X]$.G/5V"\DFOKIEK;[8L[=
M[;2!H'ADNTHYO*`\GO<"?A6',M@)V_5.<9G/JY_`D?#H.P`(R,;Y5*ZC3IY*
M`K31>2&7"?=QD)',7BI"2/RA'*2K5LD=%=$IQ4`2[".WP^%S8S?&TMOC`YRS
MQF);D\B9HYWL@BC+6MJ`?59J=!KH5\T8W+74K[26>4PAH+0:D#A1O'@.'E[D
MDE^R4D'SU6L+M5XR8N7`0LOZ@J/V)%#&,DH"Y3"9]%.6QBF41/W"0H]Q1';;
M6&^H?6.S)N]M9E_C6;7O=;RZ%T+7&I8TDU:":<#V*Y,%MR2GCQMHYQU[M/TI
MBEWL[ARHLV3<*J)+`)B^BL(HK`!1`IQ*4PIF(8/-^$!VUSFW?N^XN,E-;B9S
M\;5P%27EP[!4^SK3@5F?!XIW*V-VCSY!W5.JF`X>M%VG'F@@X343,Z2F7J0*
M$$ACMW4V^405[1Z]JJ8@8OVE$!UV^]S:"YQ/NYX&*]86/>97-!XD2RR/%?(.
M8@=X"UDZA&"?>%P^%W,V,4](`JG*N'"#1NL[<JI(-6R2J[IRX4!!LT;HE[E7
M#I<^R:2"28"<YA$"E(`B(@`".MJP"T!IXA637FU'`JNYQ`O,1[A'NTYUY0MW
MJ<[B/A]2&V+,$("8%FKJ7L;B6AWUW8(E[P52EP;2[E%<.@)K-]AW*`A%%8H`
M0$.@[@)1#N`V^X"7;<#!X[[^/QT10<>_UQ[;Y6X5+9;8MD1M''6T,+DDZ6[`
M.I3;&X8UFXQY%%#$[2`9RR>`7S;BU$"AN8=$2.?V]_+:'O>`YWBG9Y]L2_86
MFY&6I$.Z=D!_,XMLJRLH5.'25,!WI:M83ND5DR=QD47"1M@)HBL5CN(@!`$3
M=!$/CV#MYM@WZ=?M^&B*F3_<EOFCGE5A=@W736>1G'M7YULD;U%FH2%XGU6@
MN4DP.=`5TVIA3`X%%3X:(K3?"=^SD^'W%U_&.D'[)3`>*2I.VJ@+ME#MZ9$-
MU2@<OE,+=RB8I@Z"4Y1`?#1%6B]^G@0YQO>F7.##\<YC*Y=)V+9YC2@2';JT
M_(Y544Z]DAD5#M,Q):56Z23A<@E]&5135$P&7'1%+Q[1/N)QW,W"#.F9`E6:
M')'%+1G#7N,4=(%>WR$00*WB,F0[8QR*.@E$6_I2A4RF!M(IG,;M35(.B(N>
M\Y[>\WS-PU!WW$L<D_SWA5.3>P$,4017OU,DB^M/4I)142I#.)N6Q'L618Y4
MSN$U$`,7YC<")EWL>^XO`0U7:<#.1$HI1K_0I21B,./+GM`C(QYG*CA[B:8-
M*?*GBKC69!908]NX*D+MHH"*8=Z)"J$5G7[.@[B`CL(E*(AT\Y0W$3$#<-_B
M&B+3?/FD:T<OW[IJP8,D%7+U^^7(U8LFJ*9U5W;QTKVHMFS=(@F.<YBD*4.H
MAHBA0QKSM7YF>Z#6<.<>KF^7XX\9\<9&N.3)ZNO1"!S'?9`K*G1#05TA]*8I
M=1?3(F9FZD<O2G6*(D(0=$3QO<DY;PG#7BADC*2DDS;7R2AWM1Q)$+KD1?S.
M0)]HHSBG#1`PBHLUKB*BDFZ4*4Q$4&P]P@)@T1)I[/W'M#`/!3$AGIQD+KF)
MHIG>^S@G*X5E)W)B24LP%9V!Q%P=C6_DD3#N;93O_,(Z(I/NWS%,'XBB`@.V
MX]-^@_:&PC]P]=$5&GW;:--\)/=`:YTQKV1IK=+4_DU4D&QDVY&]H8S7R]U:
M'(4FQ4Y>=B'`G*'0R<@?RF[A#1%<XP+FJC<B,347,F-Y5E-52]P4;--5F*Z2
MXQKIPW3^IP4B*9O])*U]\!VCEN<"J)JIFZ=0T1+?HB1#/.&X3-E,5J\FK\A(
MMU/J%>FR(^NK$2R6P)JF2W+Z[)P41(X2W\Z?AL(`.L'>\!T3P_7?8<VSLC_2
MN^820STUC>T&@)!YJ.KJ!H::\%<.V<_<;=R3<A`:M'M-^D/U*'*T\:\[T"26
M0<T28G6A7`$2EJJ@,ZP?IIF$J:X$8&4=LA$"]2K)AMOMUUQ8WG[I_6W9&9FA
M;AKZ_MH&\HNX?#,4C!0#E'B!]>'S%L3#OS;&9B9-+=Q0W+Q1T;@X'S>S3XUM
MQ]=S8T:)L"XUR`BW35,X.`5:8,"J@]$P_P#*]!2((@'V`.J:SV9UZQMA%8V^
M"RA@C=4@,&OD]M3G);3D-9+RW])/R(Q/&>9W,:P;#C?(P@R!Z`)?\5F.I7"P
MJ]NPMNWS#U^_5RW&*Z\7&.M`=OY1L]O+.X,Y1ZO.XD?.IJ#V+RAOMHLO'O-Y
M;^&64!J?)Y$3IFG9JF"I)'QID%54&Z;3N-69=/U$D2%*@7<S<.X4T_((_84`
MU9&7Z:]==RSM^T8++A[F"K`UOK.H.),@&G#BJZTR.TXQ&\9"W8Q@/,*GOT[$
MI6).&F3KQ,,GEYB'5%J(*H*R"DHLFG.R2)1`R[.-C43'<MQ7)T%5<2`GN.Q1
M$-9NZ*^Y!U1W;D(;O?%H[#[<9*UTK+CE,LC`:T9R%^I('$CM7RMS=4\3C(W0
MX61EQ/RD-+:T!I3B0.]3)0T/&UZ)CH.':$9Q<2Q:Q[!JD!0(@U9HD;H)%Z]=
MDDPW'XCXZ[387"V>VL1;8;%Q?]?:1MCC8*4`:*<W=^G5:R/FDNKB2^N3]XF>
M2ZOE3,.47!R#Y;/G#:^Y_P"3E0H$C`MZ_,8CQ;DB/I./YM)$SL[EY,M6E=7F
MI-Q)$<E37(L].W.1,H`F'7>X'>T>W5>1`!(;[(34<;>R;QUPC+N[)@/.7+S"
M-D>QWTM[,4/,,<R4D(\#E4(Q?MGE2=1\DU35#O!-=,Y2&ZE`!ZZ@H*7V$CSP
ML)#1+F5D9M6(BXV-7G)M9NK+S"C!JBV4E)A=LW:M59&0.D*K@R:29#*',)2E
M`0`"*/#DE[:U.Y5RUH/F#DERS?42TR[>7/ANOY0B(/%<0#<C8&K%C6D*IZSF
M/;.6OKID=K.C%6,)P'?;8B;)#>P-PKJDI&V6CWCD]1;A#+?-0]MJ684HB?BW
MO:!1=LGZ5<(HBJ8"!N)1`#>`AMTT12`#Q0GCX.1PJ/+'E<1PC:1GQS$6_P!9
M)FA:+$1_]GGMP4T[<]<*4>T!,T^<^(KB/71$PJQ^PGPXO$Y(6S(V1.4N2;C,
MK%<2]MN>923%@D%0`"D,[D%ZS\PN5(.A2&,)2`&P!HB7C`GM=T'B_,5E?"O)
MGF)6Z=7)QO.'Q4OEN-F<8316Z_S#B&E*J^J)B)Q<J)A!P#0S=8X>"@#U$BD$
MR5CJGY<H%QQAD"%:6"EWVO2E:LD,[(4R+Z+E&YF[GT^\J@I.$!4!1%8H"9%8
MI3E$#%`=$4-M+]@'AG0W[&P5C(O*2`MD0<'$/;*]EQM6['#N>@@K'2$#66BB
M9NWM*8!,<IBE'NWW'<BE:P-A=]@^H.Z@_P`R9BS65>65DVECS79X^VVF*:JM
MVK8D&TEV$+"G6C&PMA4)ZX*J^H<PB<=]$3=.5_MF\/N8[I2?RSC4(^_]A/1R
MCCV05I>0.]`IR-COI.-3%I.F;@;=,)%NZ]/;RB7IHB1JF>WURGQ#'(UK#?N>
M9]C::S(#:*KV6<;8US,O#L4O(DV86"?3CI<I$4@`J:9C>D4`Z%+X:(N3?_:U
MN_(%G]#Y3>X'RHRY4'!BJ/J%44:%AFE2!T^I22<-4X!Z,BW'XIN55B_9L.B)
MP'$[VW>+W"=:YRG'^`ML!9;U5VU3G;3-V^1LLT:,8N%W;4L?]5[XV-60?N`7
M`4FY2G.F3N(($`NB)MV2O98X]YVED+#G_/'+_-EA8IKMXV4OF8F#@D0W<=HK
M(048QJ3*)B6R@AU*BB43`&QA-MHB<GQ>X%5WB7+PR>.>07)ZPXZ@(R7BHG#6
M1LD1]MQC&I20%%NO'Q2U;:2C!6*.!CMR(NB($,<VY!Z;$3NLE4Y]D"BV>FQU
MWN..'MABU(YO=Z`]8QURK2BBJ2GU.N/9*/E6+>2(5,2`95LL3M,/0!ZZ(HE<
M@>QSQ@S#9E+OFS,7+?,%S6;H,E+->LPL9.318-14,W8LCI59NFQCT3JF[4$2
MD(`F$W;HB/N%/:!PYQQGD)G`G(KF%BUH,O'RLM5:_F&.-4+(+-ZT=K-)ZO/:
M@M'/49%)MZ"Y^TJ_HJ&`JA3"!@(I=M$6LN/F+T\0'4S6@GG)(`1:PE-ON`AO
M]P!OT'H(E`!$-2%EO(?'8T&5O`@"OHK\J<S0*N)#?(AL?\I?\_W:<TG[?\(_
MF4OC0?3D_+TH;'_*7_/]VG-)^W_"/YD\:#Z<GY>E#8=P$Q2#T'X;[>'V[;:\
M)9!S`22<A[`YH-?-J5Z,<7U\!YIVU60$?#S"&^X#OX``?AZ[[%_0&VO5LCCH
M"',[Z44#"WVW.K(%G4Z@N/89%6(@)J6148I*Q<6^D"*2:BR4>3Y-N=P)GJK<
M!72;@5,>XQ`$Q0Z[=-$2(\;+]>\IT=[D"Z-HF-:S\VZ)5(F):*(I-H*-$S,S
MM5TX44<OSR#XB@E.IL/80!```VVB)PW7X``CUV`1V`1^P3?P[_;UV\>NB),\
M7S>29V,G%\ETV-ID@VL<@TA&D9+?5DY*`)V&9RBJ@&/Z*JPF$!#<!';?M+X:
M(E,T1#1%Q6UEKSV;D*TSFHQU8HAN@[E85!ZW5DXYLY$0;K/6::AEFZ2_3L,8
M`[M]$7:T1-CKF3\@6;D;:L:E3KB-&Q]"_49AY%(.G;YZ^EB(DA(YV[>@4K!X
MB"JAUTT2;")/QB`Z(G.:(AHB&B(:(AHB&B(:(AHB&B(:(LAXA]X?MT1;^B+6
M7\2_</[=#J*'@B\-0:`T4;H$0U%$-$0U`M:>(!1#0-:.`"A05K050U%131>9
M%O?LL>1F-JX@Z=VO+TVVJ+-A'E`[U:&%1-2<,W3,<I>U=N!$#&$2@4JIA$0#
M<=$13AVN4J#E_!6/VMP*O".J[+J6/&L1'MDZ_4JC`Q16;%=:1324?R,@I(]H
M&=K&)\RZ$_I%`@!HB5CDK?;-0<>/I&MR"<6[>IC$1SUJ"3RQ/[+(JIM82&K[
M%RDJQ(LY.<RJSE4H^@BD(%*)C`8"(]59Y,T#$<7*Y1FU9.:K-2"3N4VN!#*N
M';-%5](E%-!-`AW*:0^D0=@`Q@#]&B)J,WDW)CK!UIY'2-HE*D"RK5UBRAL#
M,6\4G$_64&3`UF%TDNXL#VQ-P4,<!,4J:?5,`';8B>:M8WXT,EI(E'Q[XU5;
M6!P65%T2-CU31;:5>$<@@)7(H-D3J``%\PF*`"(`.^B*-2/3O<;A3)W+%*]3
ME6O%JLI):,0C$V*4'+0;&7;148TDX^1;/EW#-8JBOIID6`I"$#;NZFT1230U
MN,3&L7>;,D$>H2G,;1-I_P#33;G/"DDGB0;FW*4%!'8!ZAW`&W31$PC"L;D&
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M;'.$&$:/Q4=+*-32/R_K?+MXYFJ`J'$!,<$1\-P$")C=/RWE2?B\^7]]DF78
M8IKZKQM#6]2+BF[Q1]&D60;1=$CW#<S%H,Q(*D[UE@6!!$Z1-Q5,<Y"F8*O`
M7-6O/(EUAG%Q7-YG(;(60;0VB:"Q9M6!K!9(YQ(G<N;'<5W+!46<1$Q2A`22
M2*7U"""BQQ`VP055RLKP&BD?EIZ.J%6<3]KED6[&!B$WDY+F2,FF;Y1!,';A
M-N4._O=."CZ:90$QC&`H`(]-15(>*:9FK)^2V./&D]#RSJC63(DA&US%%"9Q
MS!]9GZLRNDF$K97CQ!P=BZ2C%3N1;M_3!H/84ZAE-P`H)V%-A9*NU6N04O,O
M9^5B8IFUE9R474=/Y>0!#=^\77,/<<QW1Q[>[?8@``>&B(T!XA]X?MT1;^B+
M67\2_</[=$7AHB&B(:(AHB&B(:(FQ9%QEDF3SA3\J5!*GS3&NU.2K3>*M<E)
M,2P<A)JK&7GFA8Y@\,Y6,W6`HD(=-3M+L!@WW`B4^A8Z)6'TW;)N54L]_MGR
MP6&SJ(E:IE:L1$6,#`1Y3J%B:Y&F'^DCW&54/W'5,8P]"),,K8EO>0,LXZL#
M"7KS"ETE"1D$V[]-X[D&MN=@9$DXTC2I`R?/8UH8IF9E%"IH*AN(&V[1(E;O
MU")=L9V;'BTB[0).UMW7PEW9A>/2*';`5I)/O3%,RR@N2`HKT*)MQ#1$A1<'
M6NXL\94[(:L!'8ZQFUA%!K4`\=2J][L5=:)(1TC-.'#.-2CJ\U%/U09@5550
MZ@@8VW71%TN6UAD&F-6>/ZZ)"V?+M@C<?PJ1-B'19OCIC*N2%(('^7:M"@!^
MT/*4^B+Y_P#A>Q6Z#Q]CZ[)UZ&QKCPD.9Y`U]^[DW%^EJZW2+&_4%',?&I1%
M?(X*+E5L'KJN#'[3"`%W$B4O-]%L.1\:3=%K$I'P2MA/&1TB]>_,D0;UP'B!
MIE!J1HF<Y5UF27IIEZ%W,("(!HB)4GC.^3J;_%SAW487!18ROPC(D(,@2\N8
M6);(_4X%QW?[8BA-JH]CA8!$Q4!,`%$3B($1UR[0YJUX?MF/Z$M'5^2E*ZG7
MX4QQ591[5H"B1%F!5FY5U6B*\>0R("4IA*!A$`'1$VZT\=LP7!MA,LS8Z$X:
M8^=M%9&MIM)1M3H]O#QS%M&*-8XG>YL;P%&G>L*QD";_`-,A4R"81(GBEC)F
M.JKB,82J\M8213LC&:FS")G4P9!<S:0?F;)CZ3<7JQ>U-,I@22(4@!TZD2>X
M&Q4;$%!:5Q^Z92EFDGSZP7"::@H5.7L,DL<[IPW,L":QFS5,")$`P"/01V`1
M'1%V\QU>WW7'=@J='E(V#G+`@2)4F9,[DJ<?"O52(SBK8&A%%1?*1PG32W#L
M`Q^HAHB2JU<=?J\/A_&40ZC8[#U$?I2MPA5"N!EK@]BR%/'I*B0ORRS-^_64
M6=B<VYCJ#T'M+L46GE-5\2N&KS/9\7R`\GX2+ID14V%7IX1YG)K%76YU$E[`
M:(0.D$=$OI4R9FWS9C*'1;&[4R@;S:+U$M!2B-7(;'5VR53(.#I;R(;/(ZY5
MFP/F<^JN2)EXZ%<'<@QD/ETU5%VQ7P)JG1V`3@38!`VPZ+Q24S.`,L6'-=6R
M1-W.OO4HFM/&9W8-G@JUB<>G7(L:CUTY3-$C1S180:N7:QE/5'UU`,8"D`B>
M<@D""""`*++`@BDB"KA3U7"H))E("JZO7U5U.W<YOXC"(Z(O8/$/O#]NB+?T
M1>9RD,(=QMOLZ@'[=$7GZ:7Y_P"8O[M$0]-+\_\`,7]VB(>FE^?^8O[M$0]-
M+\_\Q?W:(AZ:7Y_YB_NT1#TTOS_S%_=HB`II;AN?KOT\Q=]]OAT\=M$6`30W
M'8X;_'8Q/']/3QT18!-OW=#D[M^NQD^[</N#??1%]^FGL/G';N\VQB[=WZ>G
MCHBP!$0$=CAON/?U((CU\P&Z=W[M$3<;GBVKRN5Z+<;)EZ4C;A&.7PX]J[M[
M2FK13U$E"R+>'@GD0#V86^75#U%"F57(!2CW%VT1.-]-+XJ;CT`1[B]3`781
MVVZ"/QT1#TT.XOG#NW#M\Y>[?KMMTWWT1`$T-^AP[MA\#$W[>F_PWV\-$6?3
M1^)_B7^(OCOY?AX[^'Z=$6/31_.'@'B8OAMTZ"&VVVB+'IH;#YPVW+OYR[;[
ME[/T>.VW^&B("FAUW.&_?UW,3?O\WVAOW>.B+(IH=.XX>!MMSDWVV\^W3PV\
M=$7T*9-O,<VVX>)@VW^'B'ZM$6/31_/_`!?F+MW;C^C;???_`!T18,FC_$?^
M,/$Y0_J;=/\`O[?X[:(L`FWVZ')MVE#H9/\`#U[?`/U#HB^O32_/_,7]VB+(
/)I;AY_C^8O[M$7OHB__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
